Abivax (ABVX) Stock Price, News & Analysis

Company Overview

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders. This small molecule has completed Phase 2 studies in rheumatoid arthritis and ulcerative colitis, demonstrating promising efficacy signals and a favorable tolerability profile. In addition, Abivax is exploring obefazimod’s antiviral potential in early-stage programs targeting chronic viral infections, including HIV and hepatitis B.

With operations in Europe and strategic development activities in the United States, Abivax collaborates with academic institutions and research centers to advance its pipeline. The company is led by a management team with deep expertise in biotechnology development and regulatory affairs. Under the leadership of CEO Pascal Mélin, Abivax pursues its mission to bring innovative, host-targeted therapies to patients worldwide.

Key Stats

• Today's Range: $86.57 to $90.70
• 50-Day Range: $66.57 to $90.00
• 52-Week Range: $4.77 to $92.91
• Volume: 2.94 million shs
• Average Volume: 719,474 shs
• Market Capitalization: $6.55 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $102.14
• Consensus Rating: Moderate Buy

Abivax Stock Analysis - MarketRank™

Abivax scored higher than 57% of companies evaluated by MarketBeat, and ranked 388th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Abivax has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 8 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Abivax has a consensus price target of $102.14, representing about 17.5% upside from its current price of $86.96.

Amount of Analyst Coverage

Abivax has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Abivax are expected to grow in the coming year, from ($2.83) to ($2.57) per share.

Price to Book Value per Share Ratio

Abivax has a P/B Ratio of 126.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.73% of the float of Abivax has been sold short.

Short Interest Ratio / Days to Cover

Abivax has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Abivax has recently increased by 12.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Abivax does not currently pay a dividend.

Dividend Growth

Abivax does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.73% of the float of Abivax has been sold short.

Short Interest Ratio / Days to Cover

Abivax has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Abivax has recently increased by 12.35%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.61

News Sentiment

Abivax has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Abivax this week, compared to 3 articles on an average week.

Search Interest

11 people have searched for ABVX on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.

MarketBeat Follows

3 people have added Abivax to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Abivax insiders have not sold or bought any company stock.

Percentage Held by Institutions

47.91% of the stock of Abivax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABVX Stock Analysis - Frequently Asked Questions

How have ABVX shares performed this year?

Abivax's stock was trading at $7.32 at the beginning of 2025. Since then, ABVX stock has increased by 1,088.0% and is now trading at $86.9610.

How were Abivax's earnings last quarter?

Abivax SA Sponsored ADR (NASDAQ:ABVX) released its quarterly earnings data on Monday, September, 8th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.04.

When did Abivax IPO?

Abivax (ABVX) raised $217 million in an initial public offering on Friday, October 20th 2023. The company issued 18,699,460 shares at $11.60 per share.

How do I buy shares of Abivax?

Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Abivax own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Abivax investors own include Adverum Biotechnologies (ADVM), APi Group (APG), Avino Silver & Gold Mines (ASM), Boot Barn (BOOT), G1 Therapeutics (GTHX), Howard Hughes (HHH) and KT (KT).

Company Calendar

• Last Earnings: 9/08/2025
• Today: 10/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABVX
• Previous Symbol: NASDAQ:ABVX
• CIK: 1956827
• Web: www.abivax.com
• Phone: 33-1-53-83-09-63
• Fax: N/A
• Employees: 61
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Abivax: $102.14
• High Price Target: $114.00
• Low Price Target: $74.00
• Potential Upside/Downside: +21.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.77
• Quick Ratio: 0.77

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 121.62

Miscellaneous

• Outstanding Shares: 75,570,000
• Free Float: N/A
• Market Cap: $6.34 billion
• Optionable: Not Optionable
• Beta: 0.39